BRAF Kinase Inhibitors Overview
5 Questions
0 Views

Choose a study mode

Play Quiz
Study Flashcards
Spaced Repetition
Chat to lesson

Podcast

Play an AI-generated podcast conversation about this lesson

Questions and Answers

What is the primary mechanism of action for BRAF kinase inhibitors?

  • They stimulate tumor cell proliferation.
  • They enhance immune response against tumors.
  • They promote apoptosis in tumor cells.
  • They inhibit the BRAF enzyme. (correct)
  • Which laboratory tests should be monitored while a patient is on BRAF kinase inhibitors?

  • Thyroid function tests and blood urea nitrogen (BUN).
  • Urinalysis and lipid panels.
  • Complete Blood Count (CBC), Liver Function Tests (LFTs), and serum electrolytes. (correct)
  • Electrocardiogram (ECG) and blood glucose levels.
  • What is an important dietary instruction for patients taking encorafenib?

  • Consume a high protein diet.
  • Avoid grapefruit and grapefruit juice. (correct)
  • Increase fiber intake for digestive health.
  • Limit calcium intake throughout treatment.
  • Which symptom should be reported immediately by patients taking BRAF kinase inhibitors?

    <p>Symptoms of allergic reaction or severe skin reaction.</p> Signup and view all the answers

    What precaution should patients take while using vemurafenib?

    <p>Wear sunscreen and avoid sun exposure.</p> Signup and view all the answers

    Study Notes

    BRAF Kinase Inhibitors

    • Dabrafenib (Tafinlar), encorafenib (Braftovi), and vemurafenib (Zelboraf) are examples of BRAF kinase inhibitors.
    • BRAF kinase inhibitors target the BRAF enzyme, a mutated enzyme that contributes to the growth of tumor cells.
    • Monitoring blood cell counts (CBC), liver function tests (LFTs), and serum electrolytes is important for patients taking BRAF kinase inhibitors.
    • Cardiovascular status should be monitored during treatment with BRAF kinase inhibitors.
    • Patients should be monitored for signs of deep vein thrombosis (DVT) or pulmonary embolism (PE).
    • Patients should be monitored for signs of bleeding.
    • Hypersensitivity reactions are a potential side effect of BRAF kinase inhibitors.
    • Skin lesions should be assessed in patients taking BRAF kinase inhibitors.
    • Patients should be monitored for vision changes or eye pain.
    • Encorafenib users should avoid grapefruit and grapefruit juice.
    • Vemurafenib users should wear sunscreen and avoid sun exposure.
    • BRAF kinase inhibitors can increase the risk of new skin malignancies.
    • Patients should immediately notify their healthcare provider of any suspicious lesions.
    • Patients should immediately notify their healthcare provider if they experience bleeding, liver dysfunction, changes in heart rhythm, eye pain, visual changes, fever, or thromboembolism.
    • Patients taking vemurafenib should immediately stop the medication and contact their healthcare provider if they experience an allergic reaction or severe skin reaction.

    Studying That Suits You

    Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

    Quiz Team

    Description

    This quiz covers essential information on BRAF kinase inhibitors such as Dabrafenib, Encorafenib, and Vemurafenib. It includes details on monitoring and potential side effects associated with these drugs. Understand the significance of monitoring blood counts, liver function, and managing hypersensitivity reactions.

    More Like This

    Use Quizgecko on...
    Browser
    Browser